BioCentury | Jun 26, 2019
Distillery Therapeutics

RTN4 and S1PR2 identified as targets for stroke

...inhibition of RTN4 or its receptor S1PR2 could help treat stroke. In mice, levels of RTN4...
...anti-RTN4 mAb ATI355 in Phase I testing for spinal cord injury (SCI). TARGET/MARKER/PATHWAY: Reticulon 4 (RTN4; NOGO-A...
...ATI355 in Phase I testing for spinal cord injury (SCI). TARGET/MARKER/PATHWAY: Reticulon 4 (RTN4; NOGO-A; NOGO; NOGO-B...
BioCentury | May 15, 2018
Distillery Therapeutics

Neurology

...testing to treat depression and neurobehavioral disorders. TARGET/MARKER/PATHWAY: Opioid related nociceptin receptor 1 (OPRL1; NOPR); reticulon 4...
...School of Medicine, New Haven, Conn. email: stephen.strittmatter@yale.edu Hongjiang Li Yale University Opioid related nociceptin receptor 1 (OPRL1) (NOPR) Reticulon 4...
BioCentury | Nov 30, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

New Therapeutic Targets and Biomarkers: November 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Nov 27, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Dengue fever; West Nile virus; Zika virus Cell culture studies suggest inhibiting the host factor RTN3 could help treat dengue fever, West Nile and Zika infections. In HeLa cells infected with dengue, West Nile...
BioCentury | Aug 4, 2017
Company News

ReNetX Bio launches with chronic SCI candidate

...the start of a series A round to fund its first Phase I/II trial of Nogo...
...exploring the candidate in acute spinal cord injury and glaucoma. The newco has rights to Nogo...
...was formerly known as Axerion Therapeutics. ReNetX Bio , New Haven, Conn. Business: Neurology Julian Zhu ReNetX Bio Nogo...
BioCentury | Jan 11, 2017
Distillery Therapeutics

Neurology

...a chimeric RTN4R-RTN4RL2-Fc fusion protein that inhibits the Nogo signaling ligands MAG , OMG and RTN4...
...reticulon 4 receptor-like 2 (RTN4RL2; NgR2); myelin associated glycoprotein (MAG); oligodendrocyte myelin glycoprotein (OMG; OMGP); reticulon 4 (RTN4...
...RTN4RL2; NgR2); myelin associated glycoprotein (MAG); oligodendrocyte myelin glycoprotein (OMG; OMGP); reticulon 4 (RTN4; NOGO-A; NOGO; NOGO-B...
BioCentury | Jan 7, 2016
Strategy

Imaging

...dextran amine. In a mouse model of SCI with CRYM-driven GFP expression, fluorescent imaging showed reticulon 4...
BioCentury | Jul 17, 2014
Distillery Therapeutics

Indication: Neurology

...information Neurology Nerve damage; stroke Reticulon 4 (RTN4; NOGO-A; NOGO; NOGO-B) Rat studies suggest treatment with NOGO-A...
...In rats subjected to ipsilateral stroke-induced destruction of the sensory-motor cortex, intrathecal treatment with an anti-Nogo-A...
...weeks followed by two weeks of intensive physical training increased motor function recovery compared with anti-Nogo-A...
BioCentury | Jul 29, 2013
Company News

GlaxoSmithKline neurology news

...1223249 ), a humanized mAb against reticulon 4 ( RTN4 ; NOGO-A ; NOGO ; NOGO-B...
BioCentury | Jan 21, 2013
Product Development

Solving the ALS maze

...Ph II GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) Ozanezumab (1223249) Humanized mAb against reticulon 4 (RTN4; NOGO-A; NOGO; NOGO-B...
Items per page:
1 - 10 of 48